WO2002002542A1 - Five-membered-ring compound - Google Patents
Five-membered-ring compound Download PDFInfo
- Publication number
- WO2002002542A1 WO2002002542A1 PCT/JP2001/005540 JP0105540W WO0202542A1 WO 2002002542 A1 WO2002002542 A1 WO 2002002542A1 JP 0105540 W JP0105540 W JP 0105540W WO 0202542 A1 WO0202542 A1 WO 0202542A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- alkyl
- unsubstituted
- group
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to a novel five-membered compound or a salt thereof and a pharmaceutical use thereof. More specifically, the present invention relates to the specific in vivo living L-threor 3- (3,4-dihydroxyphenyl) -N_ [3- (4-fluorophenyl) propyl] serinepyrrolidineamide
- the present invention relates to a novel 5-membered ring compound or a salt thereof, or a pharmaceutical composition thereof, which binds to a binding site, inhibits infiltration of leukocytes such as eosinophils and lymphocytes, and is thereby effective in treating various inflammations.
- bronchial asthma is a type I allergic disease involving IgE antibodies, and the development of therapeutic agents has been promoted by considering the pathogenesis of mast cells and its role.
- bronchial asthma is now considered an inflammatory disease of the respiratory tract, as seen in the opinion of the NI HZNH LBI, and bronchial asthma is referred to as "chronic epithelial exfoliated eosinophil-infiltrating bronchitis".
- Globule is considered to be an inflammation of the respiratory tract formed by inflammatory cells centered on ⁇ lymphocytes (Miwa Misawa, J. Pharmaceutical Journal, 111, 193-194 (1998).
- Inhaled steroids which are anti-inflammatory drugs, are used as the first-line drugs in Japan. and has set the guidelines (Makino Shotaira supervision, Japan allergy one Society, allergic disease treatment guidelines, P 3_65, life sciences Medellin, squid (1995)).
- Steroids are positioned as the only silver bullet for severe bronchial asthma and atopic dermatitis, but have potent effects as well as side effects (hypertension, diabetes, obesity, immunosuppression, cataracts, mental disorders, skin atrophy, etc.) Has both.
- Inhaled steroids have been developed to reduce such systemic side effects, but it is difficult to prove that steroids administered by inhalation do not circulate throughout the body. Concerns about the side effects inherent in steroids have not been dispelled.
- side effects of inhaled steroids have been reported in the U.S. and Europe, and the US FDA has issued a warning document on the risk of side effects on inhaled steroids for the treatment of bronchial asthma and nasal steroids for the treatment of allergic rhinitis. (Konig, P., Allergol. Int., 49, 1-6 (2000)) 0
- infiltration of eosinophils into lesions plays a major role not only in bronchial asthma but also in the onset of late-onset reactions and allergic dermatitis and rhinitis.
- steroids are the only specific drugs for treating allergic diseases such as bronchial asthma by suppressing the infiltration and activation of eosinophils. I'm looking for a medical spot.
- an antibody that suppresses eosinophilic inflammation
- an antibody that neutralizes interleukin 5
- interleukin 5 which causes the proliferation and differentiation of eosinophil precursor cells and prolongs the survival of mature eosinophils Neutralizing antibody
- VLA-4 Very Late Antigen 4
- CCR CCR
- a receptor for eotaxin a chemokine specific to eosinophils that causes eosinophil migration
- Small molecule antagonists against 3 Wells, TNC, et al.,
- L-threo_3- (3,4-dihydroxyphenyl) -1-N- [3- (4-fluorophenyl) propyl] serinepyrrolidineamide has a function to suppress eosinophil migration.
- An object of the present invention is to provide a compound which suppresses infiltration of leukocytes such as eosinophils and lymphocytes and is effective as a therapeutic agent for various inflammations, and a drug containing the same.
- SMBS is also expressed in rat lung membrane, and this knowledge and L-threau 3- (3, Properties of binding between 4-dihydroxyphenyl) -N- [3- (4-funoleolopheninole) propyl] serinepyrrolidineamide and [ 125 I] odosianopindolol (Sugasawa, T. et. al., J. Biol. Chem., 272, 21244-21252 (1997), WO 98/26065), and developed a new test method to suppress the onset of late-onset reactions. By screening various compounds using the method, it was found that certain 5-membered ring compounds bind to SMBS and suppress the infiltration of leukocytes such as eosinophils and lymphocytes. The present invention has been completed.
- the present invention is as follows.
- [X represents an oxygen atom or a sulfur atom.
- R 1 represents a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted monocyclic or bicyclic heterocyclic group.
- R 2 represents a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted monocyclic or bicyclic heterocyclic group, or one CON (R 6 ) R 7 .
- R 6 represents a hydrogen atom or a substituted or unsubstituted alkyl.
- R 7 represents a substituted or unsubstituted aryl, a substituted or unsubstituted monocyclic heterocyclic group, or a substituted or unsubstituted alkyl.
- _N (R 6 ) R 7 may represent a cyclic imino group.
- Y 1 is a single bond, substituted or unsubstituted alkylene, one CO (CH 2 ) n —, —SO 2 (CH 2 ) n —, one CONH (CH 2 ) n —, one C SNH (CH 2 ) n — , Or one CO 2 O (CH 2 ) n —.
- n an integer of 0 to 5.
- the wavy lines indicate the (E) or (Z) configuration.
- R 3 represents a hydrogen atom, a substituted or unsubstituted aryl, a substituted or unsubstituted monocyclic heterocyclic group, a substituted or unsubstituted bicyclic heterocyclic group, or a substituted or unsubstituted cycloalkyl.
- Y 2 represents a substituted or unsubstituted alkylene or alkenylene.
- R 5 is a hydrogen atom, or Represents a substituted or unsubstituted alkyl, or one N (R 4 ) R 5 may represent a cyclic imino group.
- R 8 represents a substituted or unsubstituted alkyl, cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted monocyclic heterocyclic group.
- R 9 represents a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted monocyclic heterocyclic group.
- R 1C) represents cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted monocyclic heterocyclic group.
- R 11 represents a hydrogen atom or an alkyl.
- R 12 represents a hydrogen atom, substituted or unsubstituted alkyl, cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylcarbonyl, or substituted or unsubstituted monocyclic heterocyclic group.
- one N (RH) R 12 may represent a cyclic imino group.
- R 13 represents a hydrogen atom or alkyl.
- R 14 represents a hydrogen atom, a substituted or unsubstituted alkyl, cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylcarbonyl, or substituted or unsubstituted monocyclic heterocyclic group.
- _N (R 13 ) R 14 may represent a cyclic imino group.
- R 15 represents a hydrogen atom or alkyl.
- R 16 is hydrogen or substituted or Represents an unsubstituted alkyl. Or one: ⁇ (1 15) 1 16 may represent a cyclic Imino group]
- N (R 4 ) R 5 is not amino, dialkylamino or acetylamino, or the 5-membered ring conjugate according to [1] or a pharmaceutically acceptable salt thereof. Salts, or their prodrugs.
- [X represents an oxygen atom or a sulfur atom.
- R 1 represents a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted bicyclic heterocyclic group.
- R 2 represents a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted bicyclic heterocyclic group.
- Y 1 is a single bond, a substituted or unsubstituted alkylene, a CO (CH 2 ) n —, or
- Wavy lines indicate (E) or (Z) configuration.
- R 3 represents a substituted or unsubstituted aryl, a substituted or unsubstituted monocyclic 5- or 6-membered heterocyclic group, or a substituted or unsubstituted bicyclic heterocyclic group.
- Y 2 represents a substituted or unsubstituted alkylene or alkenylene.
- R 4 represents a hydrogen atom, alkanoyl, aroyl, substituted or unsubstituted alkyl, alkyl rubamoyl, alkoxycarbonyl, alkylaminothiocarbinole, alkylsulfonyl, or substituted or unsubstituted arylsulfonyl.
- R 5 represents a hydrogen atom or a substituted or unsubstituted alkyl]
- [X represents an oxygen atom or a sulfur atom.
- R 1 is a hydrogen atom; an alkyl; an alkyl substituted with a hydroxyl group, a halogen atom or an amino;
- a bicyclic ring in which a 5- or 6-membered heterocyclic ring and a benzene ring containing 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom substituted with a group selected from a hydroxyl group are condensed. Represents a heterocyclic group.
- R 2 is a hydrogen atom; an alkyl; an alkyl substituted with a group selected from a hydroxyl group, a halogen atom or an amino;
- Y 1 is a single bond; linear or branched — C s alkylene; linear or branched C i — C s alkylene substituted with a hydroxyl group, a halogen atom or an amino group; one CO (CH 2 ) n — _ S 0 2 (CH 2 ) n — (n represents an integer of 0 to 5).
- R 3 is, Ariru
- a 5- or 6-membered ring containing 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom substituted with a group selected from a hydroxyl group and a hydroxyl group to a bicyclic ring in which a benzene ring and a benzene ring are fused Represents a tetracyclic group.
- Y 2 is a linear or branched c 2 —c 5 alkylene
- R 4 is a hydrogen atom; alkynyl; aroyl; alkyl; alkyl substituted with a group selected from a hydroxyl group, an alkoxy group, a halogen atom, and an amino group; alkyl group; phenolic phenol; phenolic phenol; phenolic phenol Thiol olenoyl sulfonyl; aryl sulfonyl; or aryl sulfol substituted with alkyl.
- R 5 represents a hydrogen atom; an alkyl; or an alkyl substituted with a group selected from a hydroxyl group and a halogen atom.
- R 2 is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted monocyclic or bicyclic heterocyclic group, _CON (R 6 ) R 7 , or a substituted or unsubstituted heterocyclic group.
- [S! LY 1 is a substituted or unsubstituted alkylene, one CO (CH.) N —, -SO 2 (CH 2 ) n —, one CONH (CH 2 ) n —, one CSNH (CH 2 ) n —, or one COO (CH 2 ) n —, the 5-membered ring compound according to any one of (1) to (8) Or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
- R 4 is a substituted or unsubstituted alkanoyl, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkyl group rubamoyl, a substituted or unsubstituted alkylaminothiocarbonyl, or a substituted or unsubstituted alkoxycarbonyl [1] to [14] ], The five-membered compound or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
- [Ring A represents a benzene ring or a pyridine ring.
- m represents 2 or 3.
- Y 3 represents a single bond or Carboel.
- R 17 is one or two and is independently selected from a halogen atom, Ci—C 4 alkoxy, trifluorophenol, morpholino, and methylenedioxy.
- R 18 is one or two and is independently selected from a halogen atom, —C 4 alkoxy, trifluoromethoxy and a hydroxyl group.
- R 19 is, C - CA alkyl; hydroxyl, - C 4 alkoxy, mono- or di (Ci one c 4 alkyl) Amino, Flip substituted by morpholino or carboxy one
- C 4 alkyl One C 4 alkylamine amino; or a hydroxyl group, one c 4 alkoxy, mono- or di (C 1 -c 4 alkyl) Amino represents C E _ C 4 Arukiruamino substituted with morpholino or carboxy]
- ring ⁇ is a benzene ring
- (i) Y 3 is a single bond
- the force R 19 is C ten 4 Anore Kiruamino or (ii) Y 3, is Karuponiru
- R 19 is one C 4 7 is alkyl [8] 5-membered ring I ⁇ compound or a pharmaceutically acceptable salt thereof described or prodrugs thereof.
- a medicament comprising any one of [1] to [20], the 5-membered ring compound or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
- a leukocyte infiltration inhibitor comprising the 5-membered ring compound or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
- a therapeutic agent for inflammation containing the power of any of [1] to [20], the 5-membered ring compound or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
- Alkyl includes, for example, straight-chain or branched-chain Ci-Cealkyl, and specifically, methyl, ethyl, n-propyl, 2-propyl, n-butynole, 2-butynole, 3 —Methinole-2-propyl, 1,1-Dimethinolethinole, n- pentyl, n -hexyl and the like.
- substituent in the “substituted alkyl” include a hydroxyl group, a halogen atom, an amino, a mono- or di (alkyl) amino, a carboxy, an alkoxycarbonyl, an alkoxy, a canolebamoyl, a mono- or di (alkynole) -rubamoyl, a cyclic imino group, Alkoxyalkoxy, hydroxyalkoxy, carboxyalkoxy, alkenyloxy, aryloxy, aryl, arylcarbonyl, arylylamino, arylalkylamino, alkylanoylamino, alkylthio, alkylalkyl, alkyl Lylalkoxy, arylalkyl (alkyl) amino, arylsulfonyl, alkylsulfonyl, rubamoylalkoxy, mono or di (alkyl) rubamoinolealk
- Aryl mentioned here is alkyl, alkoxy, halogen atom , May be substituted with a hydroxyl group.)
- One or two or more of the same or different ones are selected, for example, alkyl substituted with one to three, preferably one or two of the same or different substituents described above.
- particularly preferred substituents include a hydroxyl group, alkoxy, mono- or di (alkyl) amino, morpholino, carboxy, alkoxyalkoxy, hydroxyalkoxy, carboxyalkoxy and the like. .
- alkyl substituted with a halogen atom or a hydroxyl group for example, a straight-chain or branched-chain C i -Ce alkyl substituted with 1 to 3 halogen atoms such as fluorine, chlorine, bromine, iodine or 1 to 3 hydroxyl groups is mentioned. Specific examples thereof include fluoromethyl, difluoromethinole, trifluoromethyl, chloromethyl, bromomethyl, phenoleo lochinore, 2,2,2-triphnole rochetinole, 3-funololeol 1-propinole, and 3-fluorino.
- Alkoxy includes, for example, straight-chain or branched-chain C 1 -C 6 alkoxy. Specifically, methoxy, ethoxy, n-propoxy, 2-propoxy, n_butoxy, 1,1-dimethinole Ethoxy, n-pentynoleoxy, n-hexynoleoxy and the like can be mentioned.
- substituents in “substituted alkoxy” include the substituent in substituted alkyl.
- halogen-substituted alkoxy examples include, for example, a straight-chain or branched-chain C 1 -C 6 alkoxy substituted with 1 to 3 halogen atoms such as a fluorine atom, a chlorine atom, and a bromine atom. Examples thereof include fluoromethoxy, difluoromethoxy, trifluorenomethoxy, chloromethoxy, promomethoxy, 2-fluoroethoxy, 3-fluoropropoxy, 4-fluorobutoxy and the like.
- alkylamino includes, for example, an amino substituted with a linear or branched C X -C 6 alkyl, and specifically includes methylamino, ethylamino, n-propylamino, 2-propylamino, n-butylamino, 2 —Butylamino,
- dialkylamino includes, for example, an amino substituted with two straight-chain or branched-chain C i—C e-alkyls. Specifically, for example, dimethylamino, Examples include getylamino, ethylmethylamino, di-n-propylamino, di-n-butylamino and the like.
- halogen atom examples include fluorine, chlorine, bromine and iodine, and preferred examples include fluorine, chlorine and bromine.
- C 3 - Ji include 8 cycloalkyl, specifically cyclopropyl, cyclobutyl, cyclopentyl Honoré, cyclohexyl, cycloheptyl and Shikurookuchiru like to consequent opening.
- substituted cycloalkyl examples include alkyl, alkoxy, hydroxyl and the like.
- cycloalkylalkyl for example, C 3 - C 8 cycloalkyl in substitution, straight or branched c - c 6 alkyl can be mentioned, specifically, consequent opening prop Honoré methylate Honoré, cyclo Butynolemethinole, cyclopentinolechinole, cyclohexylmethyl, cyclohexylpropyl and the like.
- alkoxycarbonyl Le for example, linear or branched C i one C 6 ⁇ alkoxycarbonyl can be mentioned, specifically, main butoxycarbonyl, Etokishika Noreponiru, n- propoxy force Lupo two Honoré, 2 —Propoxy / reponyl, n-butoxycarbonyl, 2-butoxycarbonyl, 1-methylpropoxycarbonyl, 1,1-dimethinoleethoxycanolepo-nole, n-pentynoleoxycanoleponyl, n-hexyl Roxycanolevonyl and the like.
- alkanoyl includes, for example, a linear or branched C i-C alkanol, and specifically includes formyl, acetyl, propanol, butanol, pentanoyl, pipeparyl, hexanoyl, heptanoyl and the like.
- substituents in the “substituted alkanoyl” include the substituents in the substituted alkyl.
- the substituent is a hydroxyl group, an alkoxy group, a cyclic imino group, a carboxy group, an alkanoloxy phenol, a carboxyalkoxy group, Koxy canoleboninole, alkanolyloxy, aryloxy, aryl, arylcarbonylamino, arylamino, amino, mono or di (alkyl) amino, arylalkylamino, aryloyamino, alkanoylamino, alkylthio, halogen atom, etc. Is mentioned.
- Particularly preferred substituents include hydroxyl, alkoxy, dialkyla Mino, morpholino, carboxy and the like. Substitution can be carried out with 1 to 3 substituents arbitrarily selected from these, preferably 1 to 2 substituents.
- alkyl rubamoyl examples include straight-chain or branched-chain C 1 -c 6 alkyl-substituted rubamoyl. Specifically, methyl canolebamoyl, ethyl carpamoyl, n-propyl levamoyl, 2- Propyl rubamoyl, n-butylcarbamoyl, 2-butyl carbamoyl, 3-methyl-2-propyl rubamoyl, 1,1-dimethylethylcarbamoyl, n-pentylcarbamoyl, n-hexylcarbamoyl and the like.
- dialkyl rubamoyl examples include levamoyl substituted with two straight-chain or branched-chain C 6 alkyls. Specific examples include dimethylcarnomoyl, getylcanolevamoyl, and ethylmethinole. Rubamoyl, g-n-propylcarbamoyl, g-n-butylcarbamoyl and the like.
- Alkylthio includes, for example, straight chain or branched C 1, 1C 6 alkylthio, and specifically, methylthio, ethylthio, n-propylthio, 2-propylthio, n-butylthio, 2-butylthio, 1-butylthio, —Methylpropylthio, 1,1-dimethylethylthio, n-pentylthio, n-hexylthio and the like.
- alkylsulfiel examples include straight-chain or branched-chain C 1 -C 6 alkylsulfinyl, and specifically, methylsulfiel, etinolesnorefine / n- propinoresnolefenol , 2-propynoles refininole, n-butynole snorefininole, 2-butyltyl sulphi-l, 1-methinole propinoles luffiel, 1, 1 dimethinole ethinoles nofinile, n-pentinoles nofinini And n-hexisoles rufiel. -
- Alkylsulfonyl includes, for example, straight-chain or branched-chain C alkylsulfonyl, and specifically, methylsulfonyl, ethylsulfonyl, n-propynoles / lefonyl, 2-propylsnolefonyl, n— Examples include ptinolesulfonyl, 2-butylsulfonyl, 1-methylpropylsulfonyl, 1,1-dimethylethylsulfonyl, n-pentylsulfonyl, and n-hexylsulfonyl.
- straight or branched C Alkylsulfamoyl specifically, methylsulfamoyl, ethyl n-butylsulfamoyl, 2-butylsulfamoyl, 1-methylpropylsulfamoyl, 1,1-dimethylethylsulfamoyl , N-pentinolesulfamoyl, n-hexylsulfamoyl and the like.
- dialkylsulfamoyl includes, for example, sulfamoyl substituted with two straight or branched chain C x -C 6 alkyls, specifically, dimethyl n-propylsulfamoyl, di-n-butyl Sulfamoyl and the like.
- alkylaminothiocarbonyl includes, for example, straight-chain or branched-chain C 1 -C 6 alkyl-substituted aminothiocarbol, specifically methylaminothiocarbonyl, ethylaminothiocarbonyl, n _Propylaminothiocarbonyl, n-butylaminothiocarbol, n-pentylaminothiocarbonyl, n-hexylaminothiocarbonyl and the like.
- Alkylene includes, for example, straight-chain or branched-chain C 1 -C 6 alkylene, and specifically, methylene, ethylene, trimethylene, tetramethylene, pentamethylene, methinoleethylene, 2-methinoletrimethylene , 2,2-Dimethinole trimethylene, hexamethylene and the like.
- Preferred examples of “alkylene” for Y 2 include a straight-chain or branched 2 -C 6 alkylene, and more preferably a straight-chain or branched C 2 _C 4 alkylene, Particularly preferred are ethylene and trimethylene.
- substituent in the ⁇ substituted alkylene '' include a hydroxyl group, an alkoxy group, a halogen atom, an amino, an alkanoylamino and the like, and can be substituted with 1 to 3 substituents arbitrarily selected from these. Preferably, it can be substituted with one or two substituents.
- substituents in the ⁇ substituted alkylene include 2-hydroxytrimethylene.
- Alkenylene includes, for example, straight-chain or branched-chain C 3 -C 6 alkenylene, and specifically includes probelene, butenylene, 2-butenylene, pentenylene, 2-pentenylene. And 3-pentenylene.
- the "Ariru”, for example, C 6 - C 1 0 7 reels can be mentioned, specifically, phenyl, naphthyl and the like, preferably, be mentioned phenyl is.
- substituent in the “substituted aryl” include alkyl, alkoxy, nitrogen-substituted alkoxy, hydroxyl, cyclic imino, monocyclic heterocyclic, halogen atom, carboxy, cyano, amino, and mono or di (alkyl).
- Preferred substituents include alkyl, alkoxy, halogen-substituted alkoxy, hydroxyl group, cyclic imino group, monocyclic heterocyclic group, halogen atom, alkyl substituted with halogen atom or hydroxyl group, methylenedioxy, and the like. Particularly preferred are alkyl, alkoxy, halogen-substituted alkoxy, hydroxyl, cyclic imino, halogen atom, methylenedioxy and the like.
- Preferred examples of the substituent of the substituted aryl in R 1 R 2 and R 3 include alkoxy, di (alkyl) amino, nitrogen-substituted alkoxy, cyclic imino group, halogen atom, alkyl substituted with halogen atom or hydroxyl group. , Methylenedioxy, etc., and particularly preferably, C—C alkoxy, trifluoromethoxy, morpholino, halogen atom, methylenedioxy and the like.
- one to three of these substituents can be the same or different and can be substituted with aryl, and preferably one or two can be substituted.
- aryl substituted with a group selected from alkyl, alkoxy, halogen atom or hydroxyl group as a substituent include, for example, methyl, ethyl, n-propynole, 2-propyl, n-butyl, 2-butyl, methylpropyl, 1, 1-di Mechiruechiru, n - pentyl, n - the straight-chain or branched Zhen C of cyclohexyl etc.
- chi - 0 6 alkyl main butoxy, ethoxy, propoxy, 2-propoxy, n- butoxy, 1, Linear chains such as 1-dimethylethoxy, n-pentyloxy, n-hexyloxy Or one or more substituents selected from a halogen atom such as a branched-chain Ci-Ce alkoxy, fluorine, chlorine, bromine, or iodine, and a hydroxyl group, preferably one to three of the same or different, More preferably, C 6 substituted with 1 or 2 —
- C ⁇ ⁇ a reel eg phenyl, naphthyl
- phenyl eg phenyl, naphthyl
- cyclic imino group for example, a 5- or 6-membered cyclic imino group which may further contain an oxygen atom or a nitrogen atom as a ring-forming heteroatom, and the like can be mentioned. , Pyrrolidino, piperidino, morpholino and the like. _ N (R 6 )
- the cyclic imino group in R 7 may further contain an oxygen atom or a nitrogen atom as a ring-forming heteroatom, or may be a 5-membered or 6-membered cyclic imino group in which the benzene ring is fused.
- cyclic imino groups include, for example, benzopiperidino, benzopyrrolidinyl, benzomorpholino, and the like.
- the term "monocyclic heterocyclic group” includes, for example, 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom (however, an oxygen atom and a sulfur atom are simultaneously contained. And a 5- or 6-membered heterocyclic group. Specific examples thereof include cheninole, furyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, pyridyl, pyrazur, pyrimidinyl, and pyridazinyl.
- Non-aromatic heterocyclic groups such as aromatic heterocyclic groups, dioxolanyl, bilanyl, and dioxal are exemplified.
- aromatic heterocyclic group is used, and particularly preferably, pyridyl is used.
- the “bicyclic heterocyclic group” includes, for example, 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom, and a sulfur atom (however, it does not include an oxygen atom and a sulfur atom at the same time) And a fused heterocyclic group in which a 5- or 6-membered hetero ring and a benzene ring are fused.
- Benzofurinore Benzocheninore, Indolinore, Isoi And acryloyl, indazolyl, quinolyl, isoquinolyl, quinazolyl, phthalazinyl, quinoxalinyl and the like.
- substituents in the “substituted monocyclic heterocyclic group” and “substituted bicyclic heterocyclic group” include, for example, alkyl, alkoxy, halogen atom, hydroxyl group and the like.
- substituents in the “substituted monocyclic heterocyclic group” and “substituted bicyclic heterocyclic group” include, for example, alkyl, alkoxy, halogen atom, hydroxyl group and the like.
- One to three such substituents can be the same or different and can be substituted with a monocyclic heterocyclic group, and preferably one or two can be substituted.
- aroyl examples include C 7 -Caroyl, and specific examples include benzoyl and naphthoyl.
- Prodrug refers to a compound that is hydrolyzed in vivo to regenerate the 5-membered ring compound of the present invention.
- the prodrugs of the present invention include compounds produced by all the techniques for prodrugization known to those skilled in the art. For example, when the 5-membered cyclized compound of the present invention has a carboxyl group or an amino group, a compound derived from such a group into an ester group or an amide group that can be easily hydrolyzed in vivo is added to the prodrug. Equivalent to.
- the carboxyl group is converted to an alkyl such as methinole and ethyl, methinoleoxymethyl, ethynoleoxymethyl, 2-methinoleoxyethyl, Alkyloxyalkyls such as methyloxysyloxymethyl, etc.
- alkoxycarbonylalkyl such as asinoleoxymethinole, ethyloxycarbonyloxy-1-ethyl, and cycloalkyloxycarbonylalkyl, such as cyclohexyloxycarbonyloxy-1-ethyl.
- the 5-membered ring compound of the formula (1) of the present invention can be converted to a pharmaceutically acceptable salt.
- Pharmaceutically acceptable salts include acid addition salts and base addition salts.
- the acid addition salts include inorganic salts such as hydrochloride, hydrobromide, and sulfate, and organic acids such as citrate, oxalate, malate, tartrate, fumarate, and maleate.
- the base addition salts include inorganic base salts such as sodium salt and calcium salt, and organic base salts such as medalmine salt and trishydroxymethylamino methane salt. It is.
- the compound included in the present invention may have an asymmetric structure or may have a substituent having an asymmetric carbon atom, and may have an optical isomer.
- the present invention includes a mixture of these isomers and isolated ones.
- the present invention also includes solvates such as hydrates of the 5-membered ring conjugates or pharmaceutically acceptable salts thereof.
- the 5-membered ring compound of the formula (1) of the present invention can be produced by the following method or a method analogous thereto.
- Compound (1) wherein X is a sulfur atom is produced by the following method.
- X 1 represents a halogen atom such as a chlorine atom or a bromine atom
- the compound (1) in which X is a sulfur atom is obtained by reacting the thiourea compound (3) and the ⁇ -haloketone compound (4) in a solvent in the presence or absence of a base.
- the solvent include alcohol solvents such as methanol, ethanol, and 2-propanol; ether solvents such as getyl ether and tetrahydrofuran (THF); halogenated hydrocarbon solvents such as dichloromethane, dichloroethane, and chloroform; and dimethylformamide and the like.
- Examples of the base include organic amines such as triethylamine, pyridine and 4-dimethylaminoviridine, and inorganic bases such as potassium carbonate and sodium carbonate.
- the reaction temperature is selected from the range of room temperature to the boiling point of the solvent.
- Compound (1) in which X is a sulfur atom can also be produced by the following method. This production method is effective when a protecting group is required when introducing R 4 and R 5 .
- a protecting group a commonly used protecting group for an amino group can be used. The explanation will be made using methyl-2-propyloxypropyl.
- R 21 represents a substituted or unsubstituted alkyl or the like. Boc represents 2-methyl-2-propyloxycarbol.
- R 8 , R 9 , R 10 , shaku 11 , R 12 , R 13 , R 14 , R 15 and R 16 have the same meaning as above]
- the compound (6) is obtained by reacting the thiourea compound (5) with the ⁇ - ketone compound (4) in a solvent in the presence or absence of a base.
- a solvent include alcohol solvents such as methanol, ethanol, and 2-propanol; ether solvents such as ethyl ether and THF; dichloromethane; dichloroethane; Halogenated hydrocarbon solvents such as mouth-form, aprotic solvents such as dimethylformamide, and aromatic solvents such as toluene.
- the base include organic amines such as triethylamine, pyridine and 4-dimethylaminopyridine, and inorganic bases such as potassium carbonate and sodium carbonate.
- the reaction temperature is selected from the range of room temperature to the boiling point of the solvent.
- compound (7) is obtained by deprotecting compound (6) in a solvent in the presence of an acid.
- the acid include an inorganic acid such as hydrochloric acid and an organic acid such as trifluoroacetic acid.
- the solvent include ether solvents such as getyl ether, THF, and dioxane, and halogenated hydrocarbon solvents such as dichloromethane, dichloroethane, and chloroform.
- the reaction temperature is selected from the range of about 0 ° C to the boiling point of the solvent.
- Compound (7) may be added to a corresponding compound such as an alkyl halide, ester, acid chloride, acid anhydride, estenole chloroformate, snorefoninolechloride, estenole snorefonate, isocyanate or isothiocyanate in the presence of a base.
- the compound (8) can be obtained by reacting in a solvent with or without a solvent.
- Such compounds include, for example, substituted or unsubstituted alkanoyl halides, substituted or unsubstituted aroyl nolides, substituted or unsubstituted alkyl nolides, alkylcarbamoyl halides, alkyl halides, alkyl esters, alkylsulfonyl halides, Substituted or unsubstituted arylsulfonyl halides, alkyl carboxylic anhydrides, aryl carboxylic anhydrides, alkyl carboxylic acid alkyl esters, aryl carboxylic acid alkyl esters, alkyl isocyanates, alkyl isothiocyanates and the like can be mentioned.
- the solvent examples include ether solvents such as getyl ether and THF, halogenated hydrocarbon solvents such as dichloromethane, dichloroethane and chlorophonolem, aprotic solvents such as dimethylformamide, and aromatic solvents such as toluene.
- the base examples include organic amines such as triethylamine, pyridine, and 4-dimethylaminopyridine; and inorganic bases such as lithium carbonate and sodium carbonate.
- the reaction temperature is selected from the range of room temperature to the boiling point of the solvent.
- I ⁇ product (8) further, in a solvent, in the presence of a base, R 2 1 -.
- X 2 (R 2 1 are as defined before Symbol X 2 is a chlorine atom, a halogen such as bromine atom (Representing an atom)
- the solvent include ether solvents such as ethyl ether and THF, halogenated hydrocarbon solvents such as dichloromethane, dichloroethane, and chloroform, aprotic solvents such as dimethylformamide, and aromatic solvents such as toluene.
- Examples of the base include organic amines such as triethylamine, pyridine, and 4-dimethylaminopyridine; alkali metal carbonates such as potassium carbonate and sodium carbonate; sodium hydride; alkali metal hydrides such as hydrogen hydride; lithium diisopropyl; Amides and the like.
- the reaction temperature is selected from the range of about 0 ° C to the boiling point of the solvent.
- a carboxylic acid can be used as a reaction reagent.
- N, N'-dicyclohexylcarposimide N, N'-dicyclohexylcarposimide
- a condensing agent such as 1-ethyl-13_ (3-dimethylaminopropyl) carbodiimide can be used.
- the compound (1) in which X is a sulfur atom can also be produced by the following method.
- R 21 — X 2 (R 21 is as defined above) in a solvent in the presence of a base.
- X 2 represents a Happagen atom such as a chlorine atom or a bromine atom) to give a compound (10).
- Solvents include, for example, ether solvents such as dimethyl ether, THF, etc., nitrogenated hydrocarbon solvents such as dichloromethane, dichloroethane, and chloroform, aprotic solvents such as dimethylformamide, and aromatic solvents such as toluene. Is mentioned.
- the base include sodium hydride, metal hydrides such as lithium hydride, lithium diisopropylamide, and the like.
- the reaction temperature is selected from the range of room temperature to the boiling point of the solvent.
- the acid examples include inorganic acids such as hydrochloric acid, and trifluoroacetic acid. Organic acids may be mentioned.
- the solvent examples include ether solvents such as getyl ether, THF, and dioxane, and halogenated hydrocarbon solvents such as dichloromethane, dichloroethane, and chloroform.
- the reaction temperature is selected from the range of about 0 to the boiling point of the solvent.
- the starting compounds used in the above production methods 1 to 3 are produced by the following methods.
- R 3 , R 4 , R 5 , Y 1 and Y 2 are as defined above.
- R 22 represents alkyl
- the thioamine compound (12) and the isocyanate compound (13) or the dithiocarbamate (14) are reacted in a solvent to give the thioperia compound SM (3).
- the solvent include alcohol solvents such as methanol, ethanol, and 2-propanol; ether solvents such as dimethyl ether and THF; halogenated hydrocarbon solvents such as dichloromethane, dichloroethane, and chloroform; aprotic solvents such as dimethylformamide. And aromatic solvents such as toluene.
- the reaction temperature is selected from the range of room temperature to the boiling point of the solvent.
- Amine conjugate (15) can be reacted with isocyanate compound (16) or dithiocarbamate (17) in a solvent to obtain thiourea conjugate (3).
- the solvent include alcohol solvents such as methanol, ethanol, and 2-propanol; ether solvents such as getyl ether and THF; halogenated hydrocarbon solvents such as dichloromethane, dichloroethane, and chloroform; dimethylforma
- Examples include aprotic solvents such as amides and aromatic solvents such as toluene.
- the reaction temperature is selected from the range from room temperature to the boiling point of the solvent.
- R 3 , R 22 , YY 2 and B oc are as defined above.
- the thioamine compound (5) can be obtained by reacting the amine compound (18) with the isocyanate compound (13) or the dithiopotassium ester (14) in a solvent.
- the solvent include alcohol solvents such as methanol, ethanol, and 2-propanol; ether solvents such as getyl ether and THF; halogenated hydrocarbon solvents such as dichloromethane, dichloroethane, and chloroform; and dimethyl honoleamide.
- examples include non-protonic solvents and aromatic solvents such as toluene.
- the reaction temperature is selected from the range from room temperature to the boiling point of the solvent.
- Amine conjugate (15) can be reacted with isocyanate compound (19) or dithiocarbamate (20) in a solvent to obtain thioperia compound (5).
- the solvent include alcohol solvents such as methanol, ethanol, and 2-propanol; ether solvents such as getyl ether and THF; halogenated hydrocarbon solvents such as dichloromethane, dichloroethane, and chloroform; and dimethylformamide.
- Examples include aprotic solvents and aromatic solvents such as toluene.
- the reaction temperature is selected from the range from room temperature to the boiling point of the solvent.
- the isothiocyanate compounds (13), (16) and (19) are commercially available. From the hand force or the corresponding amino body, for example, Synlett. 1997, 773-774, J. Org. Chem., 1997, 62, 4539-4540, or J. Med. Chem., 1984, 27, 1570- It can be synthesized according to the method described in the document of 1574.
- the corresponding carboxylic acid can be obtained from the corresponding carboxylic acid according to a method described in a literature such as Synth. Co., un. 1997, 27, 751-756, or Indian, J. Chem., 1998, 1153-1156. Can be combined.
- the dithiol rubamic acid ester compounds (14), (17) and (20) can be obtained from commercially available compounds or from the corresponding amino compounds, for example: Chem. Soc. 1956, 1644-1649, or It can be synthesized according to a method described in a document such as Syn. Commun. 1984, 537-546.
- the ⁇ -haloketone compound (4) can be obtained from commercially available products, or from the corresponding ketone form, for example,] Med. Chem. 1987, 1497-1502, Tetrahedoron Lett. 1998, 4987-4990, or Acta Chim. Scand. 1986, B40, 700-702.
- Compound (1) in which X is an oxygen atom is produced by the following method.
- a compound of the formula (21) is dissolved in a solvent in the presence of a base to obtain a compound of the formula: R 4 (R 5 ) N-Y 2 -X 3 (R 4 and RY 2 are as defined above.
- X 3 is a chlorine atom, bromine (Representing a halogen atom such as an atom) to give compound (22).
- the solvent examples thereof include ether solvents such as getyl ether and THF, halogenated hydrocarbon solvents such as dichloromethane, dichloroethane and chloroform, aprotic solvents such as dimethylformamide, and aromatic solvents such as toluene.
- the base include metal hydrides such as sodium hydride and potassium hydride.
- the reaction temperature is selected from the range of room temperature to the boiling point of the solvent.
- the compound (23) is obtained by reacting the compound (22) with a sulfurizing reagent such as 5-sulfuride phosphorus.
- a sulfurizing reagent such as 5-sulfuride phosphorus.
- the solvent include ether solvents such as getyl ether, ⁇ and THF, halogenated hydrocarbon solvents such as dichloromethane, dichloroethane, and chloroform, aprotic solvents such as dimethylformamide, and aromatic solvents such as toluene.
- the reaction temperature is selected from the range of room temperature to the boiling point of the solvent.
- the compound (23) is reacted with a compound represented by R 3 — ⁇ 1 —NH 2 (R 3 and ⁇ 1 are as defined above) in a solvent to obtain a compound (24).
- the solvent include alcohol solvents such as methanol, ethanol, and 2-propanol; ethenol solvents such as ethynoleate ether, THF and the like; halogenated hydrocarbon solvents such as dichloromethane, dichloroethane, and chloroform; dimethylformamide And aromatic solvents such as toluene.
- the reaction temperature is selected from the range of room temperature to the boiling point of the solvent.
- Compound (1) in which X is a sulfur atom is produced by the following method.
- Y 4 is a substituted or unsubstituted alkylene, one CO (CH 2 ) n —, one SO 2 (CH 2 ) n —, one CON H (CH 2 ) n —, one CSNH (CH 2 ) n —, or one COO (CH 2 ) n — represents the imine compound (25) with the corresponding alkyl halide, ester, acid chloride.
- Acid anhydride, chloroformic acid ester, sulfonyl chloride, sulfonic acid ester, Compound (26) can be obtained by reacting a compound such as socyanate or isothiocyanate in a solvent with or without a base, or by reacting with a carboxylic acid. This reaction can be carried out in the same manner as in the method for synthesizing compound (8).
- Compound (28) can be obtained by reacting protected thiourea compound (27) with monohaloketone compound (4) in the same manner as in Production Method 1.
- the protecting group of compound (28) The compound (25) can be obtained by deprotection by the action of an acid catalyst in a solvent.
- the acid include inorganic acids such as hydrochloric acid, hydrobromic acid and sulfuric acid, and sulfonic acids such as methanesulfonic acid.
- the solvent include ether solvents such as ether and THF, alcohol solvents such as methanol, ethanol, and 2-propanol, acetic acid, and water.
- the reaction temperature is selected from the range of room temperature to the boiling point of the solvent.
- protection and deprotection techniques can be used, if necessary.
- the technology of protection and deprotection is described in detail in the literature of TW Greene and PGMSMuts, "Protecting Groups in Organic Synthesis", 1991, JOHN WILEY & SONS, INC.
- the functional group can be converted to another functional group.
- a method usually used in organic chemistry can be used. These methods are described, for example, in the following books: "Experimental Dangaku Course” Vol. 19-26 (Maruzen, 1992)
- the 5-membered ring compound (1) of the present invention or an intermediate for producing the same can be purified by an ordinary method.
- the 5-membered ring conjugate (1) of the present invention or an intermediate for producing the same has an isomer, it can be purified in the same manner.
- it can be purified by column chromatography, recrystallization and the like.
- the recrystallization solvent include alcohol solvents such as methanol, ethanol and 2-propanol; ether solvents such as getyl ether; ester solvents such as ethyl acetate; and aromatic hydrocarbon solvents such as toluene.
- ketone solvents such as acetone and the like, hydrocarbon solvents such as hexane and the like, or a mixed solvent thereof.
- an optical resolution method As a method for obtaining an optical isomer purely, for example, an optical resolution method can be mentioned.
- an optical resolution method when the compound of the present invention or an intermediate thereof has a basic substituent such as an amino group, for example, the compound of the present invention or the intermediate thereof is placed in an inert solvent (eg, methanol, ethanol, 2-propanol).
- Alcohol-based solvents such as dimethyl ether, ether-based solvents such as ethyl ether, ester-based solvents such as ethyl acetate, aromatic hydrocarbon-based solvents such as toluene, acetonitrile, etc.
- optically active native acids e.g., Monocarboxylic acids such as mandelic acid, mandelic acid, N-benzyloxyalanine and lactic acid; dicarboxylic acids such as tartaric acid, o-diisopropylidene tartaric acid and malic acid;
- an optically active amine for example, o; -phenethylamine, quinine, quinidine, cinchonidine, cinchonine, strychnine, etc.
- a method of forming a salt with an amine can also be employed.
- the temperature at which a salt is formed in the above optical resolution method includes a range from room temperature to the boiling point of the solvent. In order to improve the optical purity, it is desirable to raise the temperature once to near the boiling point of the solvent. Before the precipitated salt is collected by filtration, it can be cooled if necessary to improve the yield.
- the amount of the optically active acid or amine used is in the range of about 0.5 to about 2.0 equivalents, preferably about 1 equivalent, relative to the substrate. If necessary, crystallize in an inert solvent (for example, alcohol solvents such as methanol, ethanol, 2-propanol, ether solvents such as getyl ether, ester solvents such as ethyl acetate, and aromatic hydrocarbons such as toluene.
- Solvent, acetonitrile and the like and a mixed solvent thereof) can be recrystallized to obtain a high-purity optically active salt. If necessary, the obtained salt can be treated with an acid or a base by a usual method to obtain a free compound.
- the five-membered ring compound of the formula (1) or a salt thereof or a prodrug thereof of the present invention is useful as a medicament, and has an effect of suppressing infiltration of leukocytes such as eosinophils and lymphocytes. Accordingly, it is useful as a therapeutic agent for autoimmune disease inflammation, allergic inflammation, acute inflammation, and other inflammatory diseases with cell infiltration.
- the autoimmune disease inflammation includes, for example, rheumatism, multiple scleroderma, inflammatory bowel disease, type I diabetes and the like.
- the allergic inflammation includes, for example, bronchial asthma, inflammatory bowel disease, allergic rhinitis, atopic dermatitis, juniper, allergic conjunctivitis and the like.
- the present 5-membered ring compound is particularly useful for late-onset asthma.
- Acute inflammation includes, for example, inflammatory lung disease.
- Other inflammatory diseases include eosinophilia, eosinophilic vasculitis, eosinophilic granuloma, transplant rejection, and tumor metastasis.
- a steroid used as a therapeutic agent for inflammatory diseases, which enhances the therapeutic effect and reduces or eliminates steroids with strong side effects. It becomes possible.
- anti-allergic agents such as chemical mediator release inhibitors, antihistamines, anti-leukotrienes, and antithromboxanes
- bronchodilators such as theophylline for bronchial asthma
- Xanthine preparations, J3 stimulants and anticholinergic agents.
- non-steroids such as cyclooxygenase (COX) inhibitors It can be used in combination with anti-inflammatory drugs.
- the five-membered ring compound of the present invention or a salt thereof or a prodrug thereof can be administered orally or parenterally. When administered orally, it can be administered in a commonly used dosage form. Parenterally, it can be administered in the form of topical administration, injection, transdermal, nasal, and the like. Examples of oral or rectal preparations include capsules, tablets, pills, powders, cachets, suppositories, and liquid preparations. Examples of the injection include a sterile solution or suspension. Examples of the topical administration agent include creams, ointments, lotions, transdermal agents (ordinary patches, matritas), and the like.
- compositions and additives can be formulated in a usual manner using pharmaceutically acceptable excipients and additives.
- Pharmaceutically acceptable excipients and additives include carriers, binders, flavors, buffers, thickeners, coloring agents, stabilizers, emulsifiers, dispersants, suspending agents, preservatives, etc.
- Pharmaceutically acceptable excipients and additives include carriers, binders, flavors, buffers, thickeners, coloring agents, stabilizers, emulsifiers, dispersants, suspending agents, preservatives, etc.
- Pharmaceutically acceptable carriers include, for example, magnesium carbonate, magnesium stearate, talc, sugar, ratatose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting wax, cacao Butter and the like.
- Forcepsels can be formulated by incorporating the compound of the present invention into forcepsels together with a pharmaceutically acceptable carrier.
- the compounds of the present invention can be mixed with pharmaceutically acceptable excipients or placed in a capsule without excipients. Cassiers can be produced in a similar manner.
- the powder is formulated with a pharmaceutically acceptable powder base.
- 3 ⁇ 4 ⁇ includes talc, ratatose, starch and the like.
- Drops can be formulated with aqueous or non-aqueous ⁇ ij and one or more pharmaceutically acceptable diffusing, suspending, or dissolving agents.
- Solutions for injection include solutions, suspensions, and emulsions.
- an aqueous solution, a water-propylene glycol solution, and the like can be mentioned.
- Solutions can also be prepared in the form of solutions of polyethylene glycol or propylene glycol, which may contain water.
- Liquid preparations suitable for oral administration include the compounds of the present invention in water, Flavors, stabilizers, sweeteners, solubilizers, thickeners, and the like can be added as needed to produce.
- liquid preparations suitable for oral administration can also be produced by adding the compound of the present invention to water together with a dispersant and increasing the viscosity.
- the thickener include pharmaceutically acceptable natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and known suspending agents.
- topical preparation examples include the above-mentioned liquid preparations, creams, aerosols, sprays, powders, lotions, ointments and the like.
- the above-mentioned topical preparation can be prepared by mixing the compound of the present invention with a pharmaceutically acceptable diluent and carrier usually used.
- Ointments and creams are obtained, for example, by formulating an aqueous or oily base with a thickener and / or gelling agent added.
- the base include water, liquid paraffin, vegetable oil (peanut oil, castor oil, etc.).
- the thickener include soft paraffin, aluminum stearate, cetostearyl alcohol, propylene glycol ⁇ ⁇ ⁇ , polyethylene glycol lanolin, hydrogenated lanolin, honey and the like.
- Lotions may be added to an aqueous or oily base with one or more pharmaceutically acceptable stabilizers, suspending agents, emulsifiers, diffusing agents, thickeners, coloring agents, fragrances, etc. it can.
- Topical preparations may contain preservatives such as methyl hydroxybenzoate, propyl hydroxybenzoate, chlorothalesol, benzalconidum chloride, and anti-bacterial agents as necessary.
- the compounds of the present invention can also be administered nasally in solution spray, powder or drop fonnulations.
- the dosage and frequency of administration vary depending on the symptoms, age, body weight, dosage form, etc., but when given orally, it is usually in the range of about 1 to about 100 mg / day for an adult, preferably about 100 mg / day.
- a range of about 2 to about 500 mg, particularly preferably a range of about 5 to about 100 mg, can be administered once or in divided doses.
- When administered as an injection it can be administered in the range of about 0.1 to about 30 mg, preferably in the range of about 1 to about 20 mg, once or several times.
- Example 9 t_butyl 3- [4- (4-methoxyphenyl) -12- (phenylimino) thiazole-3 (2H) -yl] propylcarbamate (1.4) obtained by the method of (1) Using g), the reaction was carried out in the same manner as in Example 150 (2) to give the title compound (740 mg) as a colorless oil.
- N- [3- (3-Aminopropyl) -14- (4-bromophenyl) -thiazole-12 (3H) -ylidene] aniline hydrochloride (73 Omg) obtained in Example 132 and triethylamine (0.77 m 1) was dissolved in N, N-dimethylformamide (5 ml), and acetic anhydride was added dropwise in an ice bath under a nitrogen atmosphere. After stirring at the same temperature for 2 hours, a saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was crystallized from isopropyl alcohol to give the title compound (58 Omg). Melting point: 155-157 ° C
- Example 168 A mixture of the compound obtained in Example 168 (1.1 g), a 5% aqueous sodium hydroxide solution (2 ml) and methanol (15 ml) was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure, water was added to the residue, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (form: methanol: 99: 1) to give the title compound (923 mg).
- Example 171 By a method similar to that of Example 171, the amino compound obtained by the method of Example 132 or Example 9 was reacted with methanesulfonyl chloride or p-toluenesulfonyl chloride to obtain a sulfonamide compound shown in Table 14. .
- Ts represents a tosyl group.
- Example 79 or Example 108 By the same method as in Example 1 77, the amino compound obtained by the method of Example 9, Example 79 or Example 108 was reacted with ethyl isocyanate or ethyl ethyl isothiocyanate to give perylene and thioperia shown in Table 15 The compound was obtained.
- Lithium aluminum hydrogen (1.0 g) was suspended in tetrahydrofuran (20 Om 1), and a solution of the compound (3.0 g) obtained in (2) above in tetrahydrofuran (10 Oml) was added dropwise in an ice bath under a nitrogen atmosphere. did. One hour later, water was added to the reaction mixture to crush excess lithium aluminum hydride, and then a 10 N aqueous sodium hydroxide solution was added. After the resulting slurry was dried over sodium sulfate, the filtrate was concentrated under reduced pressure to obtain the title compound (2.61 g).
- the compound (313 mg) obtained in the above (2) was dissolved in N, N-dimethylformamide (3 ml), and sodium hydride (56 mg, 60% oil-dispurgeon) was placed in a water bath under a nitrogen atmosphere. The mixture was added and stirred for 30 minutes. Benzyl bromide (179 mg) was added to the reaction mixture, and the mixture was returned to room temperature and stirred for 1 hour. The reaction mixture was poured into a 10% aqueous solution of citric acid under ice-cooling, and extracted with chloroform. The organic layer was washed with brine, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography [ n- hexanemonoacetate (5: 1)] to give the title compound (137 mg) as an oil.
- Example 208 (2) Using the compound (313 mg) obtained in Example 208 (2) and 4-cyclomouth benzyl bromide (216 mg), a reaction was carried out in the same manner as in Examples 208 (3) and (4), and the title compound was obtained. 152 mg) as the hydrochloride salt.
- Example 210 (1) Using the compound (276 mg) obtained in Example 210 (1), a reaction was carried out in the same manner as in Example 208 (3), (4) to obtain the title compound (92 mg) as a hydrochloride.
- Example 208 The compound (30 mg) obtained in (2) and triethylamine (10 lmg) were rapidly dissolved in tetrahydrofuran (30 ml), and methanesulfonyl chloride (115 mg) was added dropwise under ice cooling. After stirring at the same temperature for 1.5 hours, N-methyl-4-chlorobenzylamine (1.04 g) was added dropwise to the reaction mixture, and the mixture was further stirred for 1 hour. Water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, dried over sodium sulfate, and the solvent was distilled off under reduced pressure.
- Example 210 Using the compound (20 mg) obtained in (1), a reaction was carried out in the same manner as in Example 212 to obtain the title compound (145 mg) as a hydrochloride.
- Example 106 The conjugate (1.74 g, free amino form) obtained in Example 106 was dissolved in ethanol (1 Oml), and ethyl acrylate (0.48 ml) in ethanol (3 Oml) was taken under ice-cooling for 15 minutes. The solution was added dropwise. After stirring at room temperature overnight, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography [chloroform-form-methanol (30: 1)] to give the title compound (1.87 g) as an oil.
- N N "-di-tert-butoxycarbol-N, 1- ⁇ 3- [4- (4-fluorophenyl) -1 2-[(4-fluorophenyl) imino] thiazole-3 (2H) _ Yl] propyl ⁇ guanidine
- Example 116 The compound (837 mg, free amino form) obtained in Example 116 was dissolved in ethanol (10 ml), and 1,3-bis (ter-butoxycarbonyl) -12-methylisothioate was added at room temperature under a nitrogen atmosphere. Add rare (639mg) and stir for 7 hours Was. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel gel chromatography [n-hexane-ethyl acetate ( 5 : D)] to give the title compound (1.12 g).
- Example 195 The compound (522 mg, hydrochloride) obtained in Example 195 was suspended in tetrahydrofuran (3 Oml), and the mixture was suspended at room temperature under a nitrogen atmosphere by the method of Ka tritzky, AR et al. (J. Org. Chem., 2000, 2000). 65 (8080-8082) synthesized by adding 1- (1H-1,2,3-benzotriazole-1-1-yl) -1-1-morpholinomethanimine (1.16 g) and stirring free for one day did. A 10% aqueous sodium carbonate solution was added to the reaction mixture, and the mixture was extracted with chlorophonolem.
- the reaction mixture was filtered, and the filtrate was washed twice with a stoichiometric form (1 ml), and the filtrate was washed twice with a saturated aqueous solution of sodium hydrogencarbonate (2 ml) and then with water (2 ml). .
- the organic layer was passed through a NyuTsuta filter sulfate Maguneshiumu to give 2 Kaiaraire in black port Holm (1 m 1), Inclusive, the filtrate was concentrated to give the title compound (22m g).
- Example 106 To a mixture of the compound obtained in Example 106 (1.0 g, free amino form), triethylamine (0.72 ml) and tetrahydrofuran (5 ml) was added 2,2,2-trifluoroethylene trifluoromethanesulfonate. To the reaction mixture was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography [n-hexane monoacetate (85:15)] to give the title compound (80 ° mg) as an oil.
- Lithium borohydride (17 Omg) was added to a solution of the compound (3 g) obtained in (1) above in tetrahydrofuran (20 ml), and the mixture was stirred at room temperature for one day. After water was added to the reaction mixture, it was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel gel chromatography [n-hexane monoethyl acetate (1: 1)] to give the title compound (2.14 g) as an amorphous solid.
- Example 216 Using the amino compound (1.87 g) obtained in Example 216, the title compound (2.16 g) was obtained as an oil in the same manner as in Example 32 1 (1).
- Example 321 A 4N aqueous sodium hydroxide solution (5 ml) was added dropwise to a solution of the compound (3 g) obtained in (1) in ethanol (5 ml), and the mixture was stirred at room temperature for 4 hours. After water was added to the reaction mixture, the mixture was acidified with a 10% aqueous solution of citric acid and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (2.92 g) as a foam.
- Example 322 Using the esterified compound (850 mg) obtained in (1), a reaction was carried out in the same manner as in Example 32 7 (1) to obtain the title compound (71′5 mg) as a foam.
- Example 32 7 (1) Using the esterified compound (850 mg) obtained in (1), a reaction was carried out in the same manner as in Example 32 7 (1) to obtain the title compound (71′5 mg) as a foam.
- Example 32 7 (1) N_ ⁇ 3 -— [2 -— ((4-Chloro-2-methoxyphenyl) imino] _4-I- (4-fluorophenyl) thiazole-3 (2H) -yl] propyl ⁇ — ⁇ -alanine
- Example 252 The amino compound (3.3 g) obtained in Example 252 was used as a starting material, and the title compound (4.1 g) was obtained as an oil in the same manner as in Example 321 (1).
- Example 253 Using the amino acid conjugate (90 Omg) obtained in Example 253, the title compound (1.08 g) was obtained as an oil in the same manner as in Example 321 (1).
- Example 277 Using the compound (80 Omg) obtained in Example 277, the reaction was carried out in the same manner as in Example 327 (1), and crystallized from ethyl acetate to obtain the title compound (726 mg).
- Example 234 Using the compound (80 Omg) obtained in Example 234, the reaction was carried out in the same manner as in Example 327 (1), and crystallized from ethyl acetate to obtain the title compound (726 mg).
- Example 321 The compound (1.1 g) obtained in (2) was dissolved in tetrahydrofuran (2 Om 1), and sodium hydride (41 Omg, 60% oil-dispurgeon) was placed in an ice bath under a nitrogen atmosphere. ) was added several times and stirred for 30 minutes. Ethyl bromoacetate (0.45 ml) was added to the reaction mixture, and the mixture was returned to room temperature and stirred for 6 hours. The reaction mixture was poured into a 5% aqueous solution of citric acid under ice cooling, and extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography [n-hexane monoacetate (8: 2)] to give the title compound (98 Omg) as a colorless oil.
- the reaction mixture was filtered, and the filtrate was washed twice with dichloromethane (1 ml), and the filtrate was washed twice with a saturated aqueous solution of sodium hydrogen carbonate (2 ml) and subsequently with water (2 ml).
- the organic layer was passed through a filter containing magnesium sulfate, washed twice with dichloromethane (lm 1), and the filtrate was concentrated. 90% trifluoroacetic acid (2 ml) was added to the residue, and the mixture was stirred at room temperature for 2 hours, and then the mixture was concentrated.
- Example 95 The compound obtained in Example 95 (3.0 g, hydrochloride) was suspended in tetrahydrofuran (36 ml), and diisopropylethylamine (5 ml) was added dropwise in an ice bath under a nitrogen atmosphere. Stirred for minutes. 4-Nitrophenyl chloroformate (1.19 g) was added to the reaction mixture, and the mixture was stirred for 3.5 hours. To the reaction mixture was added a saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue is crystallized from n-hexane monoethyl acetate Then, the title compound (2.57 g) was obtained.
- Example 348 The compound (108 mg) obtained in Example 348 was dissolved in dichloromethane (3 ml), N, N-dimethylethylenediamine (33 mg) was added at room temperature under a nitrogen atmosphere, and the mixture was stirred for 1 hour. A 1% aqueous sodium hydroxide solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was washed with brine, dried over sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (84 mg) as a pale yellow solid.
- Example 195 Using the compound obtained in Example 195 (2.0 g, hydrochloride) and bromoacetyl mouthride (663 mg), the reaction was carried out in the same manner as in Example 168. The title compound (1.2 g, amorphous) was obtained. ).
- Example 356 was reacted with various amines by the same reaction as in Example 357 to obtain the compounds shown in Table 22.
- Acetic anhydride (48 ⁇ l) was added to a mixture of the compound obtained in Example 362 (25 Omg, hydrochloride), triethylamine (0.22 ml) and tetrahydrofuran (3 ml) under ice cooling, and the mixture was stirred for 2 hours. Water was added and extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography [2% methanol-one-mouth form] to give the title compound (23 Omg).
- Example 362 96 Omg, hydrochloride
- 2-methoxyacetyl chloride 0.2 ml
- Example 363 The compound obtained in Example 363 was converted to Boc according to a conventional method, and a mixture of the obtained compound (1.00 g), sodium hydride (0.24 g), and dimethylformamide (5 ml) was added for 0.5 hour. After stirring, 2-methoxyethyl bromide was added and stirred for 6 hours. A 10% aqueous solution of taenoic acid was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and the solvent was distilled off under reduced pressure.
- the residue was purified by silica gel column chromatography [form ethyl acetate monoethyl acetate (4: 1), 4N hydrochloric acid / dioxane (2 ml) was added, the mixture was stirred at room temperature for 3 hours, and the solvent was distilled off under reduced pressure. Ammonia water was added to the residue, and the mixture was extracted with a mouth-mouth form. The organic layer was washed with a saturated saline solution, dried over sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (185 mg).
- Example 427 It was synthesized by a combinatorial method. That is, the compound obtained in Example 427 was subjected to Bocido according to a conventional method, and a dichloromethane solution (43.8 ⁇ ( ⁇ 1 / m 1) of the obtained compound was added with N, N-dimethylinoformol of ethylethylamine hydrochloride.
- the organic layer was passed through a filter containing magnesium sulfate, washed twice with dichloromethane (lm 1), and the filtrate was concentrated.
- 90% trifluoroacetic acid (2 ml) was added to the residue, and the mixture was stirred at room temperature for 2 hours, and then the mixture was concentrated.
- the residue was dissolved in dichloromethane (2 ml), an excess amount of ion exchange resin (Dowe xl-X8, OH type) was added, and the mixture was stirred at room temperature for 1 hour.
- the reaction mixture was filtered, and the filtrate was washed twice with dichloromethane (lm 1), and the filtrate was concentrated to obtain the title compound.
- Example 415 The compound obtained in Example 415 was subjected to Boc cyclization according to a conventional method, and the obtained compound (1.
- the reaction mixture was filtered and the filtrate was washed twice with dichloromethane (1 ml), and the filtrate was washed twice with a saturated aqueous sodium hydrogen carbonate solution (2 ml) and subsequently with water (2 ml).
- the organic layer was passed through a filter containing magnesium sulfate, washed twice with dichloromethane (1 ml), and the filtrate was concentrated. After adding 90% trifluoroacetic acid (2 ml) to the residue and stirring at room temperature for 2 hours, the mixture was concentrated to give the title compound as trifluoromethyl acetate.
- Lithium borohydride (2.0 g) was added to a solution of the ester compound (10 g) in which the hydrobromide salt obtained in the above (1) was fried and tetrahydrofuran (300 ml). The mixture was stirred at room temperature. To the reaction mixture was added 10% aqueous citric acid under ice-cooling to crush excess lithium borohydride, followed by extraction with chloroform. The organic layer was washed with brine, dried over sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (8.3 g).
- Tiophosgene (0.8 m) was added to a tetrahydrofuran (1 Oml) solution containing 2- (trifluoromethoxy) ferrin (1.8 g) and triethylamine (2.9 ml) in an ice bath under a nitrogen atmosphere. l) was added dropwise. Thereafter, the temperature was returned to room temperature and the mixture was stirred for 2 hours. To the reaction mixture was added t-butyl 3- (aminopropyl) carbamate (1.39 g), and the mixture was further stirred for 2 hours. Water was added to the reaction mixture, which was extracted with ethyl acetate.
- 2,3-Methylenedioxyphenamine (698 mg) obtained by the method described in the document of Nevinore et al. (Neville, CF et al, J. Chem. Soc. Perkin Trans. 1, 1991, 259-262). ), T-butynole 3-isothiocyanatopropylcarbamate (1.1 g) and dioxane (1 Oml) were heated and refluxed under a nitrogen atmosphere. After 4 hours, the reaction mixture was concentrated under reduced pressure. The residue was crystallized from getyl ether-n-hexane to give the title compound (803 mg).
- the mixture was suction-filtered and washed (200 ⁇ l of ice-cold Tris-saline buffer was added and suctioned), and the reaction solution on the 96-well Attee plate was suction-filtered and washed four times on a multi-screen plate.
- the glass fiber filter paper at the bottom of the multi-screen plate was punched out, and the y-dose of [ 125 I] -odosianopindolol trapped on the filter paper was measured, and this was used as the binding amount.
- the amount of binding in the presence of DMS ⁇ (final concentration: 1%) is defined as the total amount of binding, and 10 O ML—Threo-3- (3,4-dihydroxypheninole) -N— [3- (4-fluorofluor) propyl ]
- the amount of binding in the presence of serine pyrrolidineamide was taken as the non-specific binding amount.
- the value obtained by subtracting the non-specific binding amount from the total binding amount is the specific binding amount.
- Binding activity of the compound is calculated according to the following equation, the test I arsenide compound is [125 1] - a percentage inhibit specific binding to the ® over de Xia Bruno pin Dror La Tohaimaku SMB S Was. (Binding amount in the presence of test compound-non-specific binding amount)
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60140748T DE60140748D1 (de) | 2000-06-30 | 2001-06-28 | Thiazol-derivate zur verwendung als entzündungshemmende mittel |
KR1020027017947A KR100758775B1 (ko) | 2000-06-30 | 2001-06-28 | 5원환 화합물 |
DK01943850.6T DK1300401T3 (da) | 2000-06-30 | 2001-06-28 | Thiazolderivater til anvendelse som antiinflammatoriske midler |
AT01943850T ATE451102T1 (de) | 2000-06-30 | 2001-06-28 | Thiazol-derivate zur verwendung als entzündungshemmende mittel |
CA002413000A CA2413000C (en) | 2000-06-30 | 2001-06-28 | Five-membered ring compounds |
EP01943850A EP1300401B1 (en) | 2000-06-30 | 2001-06-28 | Thiazole derivatives for use as antiinflammatories |
AU2001266345A AU2001266345B2 (en) | 2000-06-30 | 2001-06-28 | Five-membered-ring compound |
AU6634501A AU6634501A (en) | 2000-06-30 | 2001-06-28 | Five-membered-ring compound |
US10/312,692 US6919361B2 (en) | 2000-06-30 | 2001-06-28 | Five-membered-ring compound |
JP2002507796A JP3785397B2 (ja) | 2000-06-30 | 2001-06-28 | 5員環化合物 |
US11/111,845 US7396842B2 (en) | 2000-06-30 | 2005-04-22 | Five-membered cyclic compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-198074 | 2000-06-30 | ||
JP2000198074 | 2000-06-30 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/111,845 Division US7396842B2 (en) | 2000-06-30 | 2005-04-22 | Five-membered cyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002002542A1 true WO2002002542A1 (en) | 2002-01-10 |
Family
ID=18696291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/005540 WO2002002542A1 (en) | 2000-06-30 | 2001-06-28 | Five-membered-ring compound |
Country Status (15)
Country | Link |
---|---|
US (2) | US6919361B2 (ja) |
EP (2) | EP1669070A3 (ja) |
JP (1) | JP3785397B2 (ja) |
KR (2) | KR100758775B1 (ja) |
CN (2) | CN100369903C (ja) |
AT (1) | ATE451102T1 (ja) |
AU (2) | AU2001266345B2 (ja) |
CA (1) | CA2413000C (ja) |
CY (1) | CY1109863T1 (ja) |
DE (1) | DE60140748D1 (ja) |
DK (1) | DK1300401T3 (ja) |
ES (1) | ES2336425T3 (ja) |
PT (1) | PT1300401E (ja) |
TW (1) | TWI313266B (ja) |
WO (1) | WO2002002542A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003057693A1 (fr) * | 2001-12-28 | 2003-07-17 | Sumitomo Pharmaceuticals Co., Ltd. | Composes cycliques a 5 chainons |
EP1348433A1 (en) * | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
WO2005000825A1 (ja) * | 2003-06-27 | 2005-01-06 | Dainippon Sumitomo Pharma Co., Ltd. | チアゾールイミン類およびオキサゾールイミン類 |
JP2006512321A (ja) * | 2002-11-21 | 2006-04-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | カルボキサミド |
WO2006118268A1 (ja) * | 2005-04-28 | 2006-11-09 | Dainippon Sumitomo Pharma Co., Ltd. | 慢性閉塞性肺疾患治療剤 |
JP2007015999A (ja) * | 2005-07-11 | 2007-01-25 | Sumitomo Chemical Co Ltd | イミノチアゾール化合物の製造方法 |
WO2007132546A1 (ja) * | 2006-05-11 | 2007-11-22 | Dainippon Sumitomo Pharma Co., Ltd. | チアゾール誘導体を有効成分とする医薬 |
KR100863239B1 (ko) * | 2007-05-23 | 2008-10-15 | 한국과학기술연구원 | 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는t-형 칼슘 채널 저해제 |
WO2009131171A1 (ja) | 2008-04-25 | 2009-10-29 | 大日本住友製薬株式会社 | 新規5員環化合物 |
WO2009131170A1 (ja) | 2008-04-25 | 2009-10-29 | 大日本住友製薬株式会社 | 5員環化合物 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100848437B1 (ko) * | 2003-10-10 | 2008-07-28 | 샤프 가부시키가이샤 | 콘텐츠 재생 장치, 콘텐츠 재생 장치의 제어 방법, 콘텐츠 기록 매체, 및 컴퓨터 판독 가능한 기록 매체 |
MY162179A (en) * | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
JPWO2006051704A1 (ja) * | 2004-11-15 | 2008-05-29 | 大正製薬株式会社 | イミン化合物 |
WO2007140439A2 (en) | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
WO2008121558A1 (en) | 2007-03-28 | 2008-10-09 | Abbott Laboratories | 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands |
US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
JP2010527929A (ja) | 2007-05-18 | 2010-08-19 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物 |
US9193713B2 (en) * | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8859596B2 (en) | 2008-09-16 | 2014-10-14 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
CA2756178A1 (en) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US9650369B2 (en) * | 2012-09-28 | 2017-05-16 | Xavier University Of Louisiana | Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998026065A1 (en) | 1996-12-12 | 1998-06-18 | Vetigen | Mammalian icyp (iodocyanopindolol) receptor and its applications |
WO2001007424A1 (fr) * | 1999-07-22 | 2001-02-01 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | 2-arylimino-2,3-dihydrothiazoles et leur utilisation comme ligands des recepteurs de la somatostatine |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE941288C (de) * | 1950-10-31 | 1956-04-05 | Goodrich Co B F | Verfahren zur Herstellung substituierter 2-Imino-4-thiazoline oder von Salzen derselben bzw. von substituierten 2-Aminothiazolen |
US7076307B2 (en) * | 2002-05-09 | 2006-07-11 | Boveja Birinder R | Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders |
CA2389773A1 (en) * | 1999-11-05 | 2001-05-10 | Robert Glen | Activators of soluble guanylate cyclase |
US20030208212A1 (en) * | 1999-12-07 | 2003-11-06 | Valerio Cigaina | Removable gastric band |
DE19959825C1 (de) * | 1999-12-10 | 2001-07-26 | Dorma Gmbh & Co Kg | Schiebewand mit mehreren seitlich verschiebbaren Wandelementen |
US6885888B2 (en) * | 2000-01-20 | 2005-04-26 | The Cleveland Clinic Foundation | Electrical stimulation of the sympathetic nerve chain |
US6708064B2 (en) * | 2000-02-24 | 2004-03-16 | Ali R. Rezai | Modulation of the brain to affect psychiatric disorders |
US6639077B2 (en) * | 2000-03-23 | 2003-10-28 | Merck Frosst Canada & Co. | Tri-aryl-substituted-ethane PDE4 inhibitors |
US6684105B2 (en) * | 2001-08-31 | 2004-01-27 | Biocontrol Medical, Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US7054686B2 (en) * | 2001-08-30 | 2006-05-30 | Biophan Technologies, Inc. | Pulsewidth electrical stimulation |
US7831308B2 (en) * | 2002-02-01 | 2010-11-09 | The Cleveland Clinic Foundation | Neural stimulation delivery device with independently moveable delivery structures |
US7715924B2 (en) * | 2002-02-01 | 2010-05-11 | The Cleveland Clinic Foundation | Adjustable simulation device and method of using same |
AU2003210752A1 (en) * | 2002-02-01 | 2003-09-02 | The Cleveland Clinic Foundation | Modulation of the pain circuitry to affect chronic pain |
US7689276B2 (en) * | 2002-09-13 | 2010-03-30 | Leptos Biomedical, Inc. | Dynamic nerve stimulation for treatment of disorders |
US20040015205A1 (en) * | 2002-06-20 | 2004-01-22 | Whitehurst Todd K. | Implantable microstimulators with programmable multielectrode configuration and uses thereof |
US7292890B2 (en) * | 2002-06-20 | 2007-11-06 | Advanced Bionics Corporation | Vagus nerve stimulation via unidirectional propagation of action potentials |
US20040210270A1 (en) * | 2002-07-26 | 2004-10-21 | John Erickson | High frequency pulse generator for an implantable neurostimulator |
US7209790B2 (en) * | 2002-09-30 | 2007-04-24 | Medtronic, Inc. | Multi-mode programmer for medical device communication |
US20040172084A1 (en) * | 2003-02-03 | 2004-09-02 | Knudson Mark B. | Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) |
US7613515B2 (en) * | 2003-02-03 | 2009-11-03 | Enteromedics Inc. | High frequency vagal blockage therapy |
US7167750B2 (en) * | 2003-02-03 | 2007-01-23 | Enteromedics, Inc. | Obesity treatment with electrically induced vagal down regulation |
US7844338B2 (en) * | 2003-02-03 | 2010-11-30 | Enteromedics Inc. | High frequency obesity treatment |
US7444184B2 (en) * | 2003-05-11 | 2008-10-28 | Neuro And Cardial Technologies, Llc | Method and system for providing therapy for bulimia/eating disorders by providing electrical pulses to vagus nerve(s) |
US7149574B2 (en) * | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
US7263405B2 (en) * | 2003-08-27 | 2007-08-28 | Neuro And Cardiac Technologies Llc | System and method for providing electrical pulses to the vagus nerve(s) to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders with a stimulator, comprising bi-directional communication and network capabilities |
US7617002B2 (en) * | 2003-09-15 | 2009-11-10 | Medtronic, Inc. | Selection of neurostimulator parameter configurations using decision trees |
US7184837B2 (en) * | 2003-09-15 | 2007-02-27 | Medtronic, Inc. | Selection of neurostimulator parameter configurations using bayesian networks |
US7252090B2 (en) * | 2003-09-15 | 2007-08-07 | Medtronic, Inc. | Selection of neurostimulator parameter configurations using neural network |
US7239926B2 (en) * | 2003-09-15 | 2007-07-03 | Medtronic, Inc. | Selection of neurostimulator parameter configurations using genetic algorithms |
US7418292B2 (en) * | 2003-10-01 | 2008-08-26 | Medtronic, Inc. | Device and method for attenuating an immune response |
EP1781372A1 (en) * | 2004-07-20 | 2007-05-09 | Medtronic, Inc. | Therapy programming guidance based on stored programming history |
-
2001
- 2001-06-28 ES ES01943850T patent/ES2336425T3/es not_active Expired - Lifetime
- 2001-06-28 DE DE60140748T patent/DE60140748D1/de not_active Expired - Lifetime
- 2001-06-28 AT AT01943850T patent/ATE451102T1/de active
- 2001-06-28 AU AU2001266345A patent/AU2001266345B2/en not_active Ceased
- 2001-06-28 CA CA002413000A patent/CA2413000C/en not_active Expired - Fee Related
- 2001-06-28 DK DK01943850.6T patent/DK1300401T3/da active
- 2001-06-28 US US10/312,692 patent/US6919361B2/en not_active Expired - Fee Related
- 2001-06-28 KR KR1020027017947A patent/KR100758775B1/ko not_active IP Right Cessation
- 2001-06-28 WO PCT/JP2001/005540 patent/WO2002002542A1/ja active Application Filing
- 2001-06-28 EP EP05025661A patent/EP1669070A3/en not_active Withdrawn
- 2001-06-28 CN CNB018146139A patent/CN100369903C/zh not_active Expired - Fee Related
- 2001-06-28 JP JP2002507796A patent/JP3785397B2/ja not_active Expired - Fee Related
- 2001-06-28 CN CNA2006100818928A patent/CN1944417A/zh active Pending
- 2001-06-28 EP EP01943850A patent/EP1300401B1/en not_active Expired - Lifetime
- 2001-06-28 KR KR1020077015693A patent/KR100824156B1/ko not_active IP Right Cessation
- 2001-06-28 AU AU6634501A patent/AU6634501A/xx active Pending
- 2001-06-28 PT PT01943850T patent/PT1300401E/pt unknown
- 2001-06-29 TW TW090115944A patent/TWI313266B/zh not_active IP Right Cessation
-
2005
- 2005-04-22 US US11/111,845 patent/US7396842B2/en not_active Expired - Fee Related
-
2010
- 2010-03-02 CY CY20101100202T patent/CY1109863T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998026065A1 (en) | 1996-12-12 | 1998-06-18 | Vetigen | Mammalian icyp (iodocyanopindolol) receptor and its applications |
WO2001007424A1 (fr) * | 1999-07-22 | 2001-02-01 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | 2-arylimino-2,3-dihydrothiazoles et leur utilisation comme ligands des recepteurs de la somatostatine |
Non-Patent Citations (7)
Title |
---|
ACHESO R. MORRIN ET AL.: "7-Alkylation and 7-sulfonylation of 5,6-dihydroimidazolo(2,1-b)-thiazole", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, vol. 8, 1980, pages 1773 - 1778, XP002947211 * |
NEMES ANDRAS ET AL.: "Synthesis and investigation of some N-(2-thiazolyl)-ethylenediamine derivatives", ACTA CHIMICA ACADEMIAE SCIENTIARUM HUNGARICAE, TOMUS, vol. 78, no. 3, 1973, pages 283 - 291, XP002947210 * |
SUGASAWA, T. ET AL., J. BIOL. CHEM., vol. 267, 1997, pages 21244 - 21252 |
SUGASAWA, T. ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 21244 - 21252 |
SUGASAWA, T.; MOROOKA, S.: "Recent Advances in Cellular and Molecular Biology", vol. 3, 1992, PEETERS PRESS, pages: 223 - 227 |
TSATSAS G. ET AL.: "Synthesis and facile ring-opening of 5,6-dihydro-7H-thiazolo (3,2-a)pyrimidin-7-one and its quaternary halide", CHIMIKA CHRONIKA NEW SERIES 1, vol. 1, no. 3-4, 1972, pages 188 - 192, XP002947213 * |
YAMAMOTO YUICH ET AL.: "Proton-induced ring transformation of 2-imino-3-thiocarbamoyl-4-thiazoline", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 32, no. 11, 1984, pages 4292 - 4299, XP002947212 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003057693A1 (fr) * | 2001-12-28 | 2003-07-17 | Sumitomo Pharmaceuticals Co., Ltd. | Composes cycliques a 5 chainons |
EP1348433A1 (en) * | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
WO2003082277A1 (en) * | 2002-03-28 | 2003-10-09 | Warner-Lambert Company Llc | Thiazol-2-yl-imine compounds as pde-7 inhibitors |
JP4732757B2 (ja) * | 2002-11-21 | 2011-07-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | カルボキサミド |
JP2006512321A (ja) * | 2002-11-21 | 2006-04-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | カルボキサミド |
WO2005000825A1 (ja) * | 2003-06-27 | 2005-01-06 | Dainippon Sumitomo Pharma Co., Ltd. | チアゾールイミン類およびオキサゾールイミン類 |
WO2006126581A1 (ja) * | 2005-04-28 | 2006-11-30 | Dainippon Sumitomo Pharma Co., Ltd. | 組合せ医薬 |
WO2006118268A1 (ja) * | 2005-04-28 | 2006-11-09 | Dainippon Sumitomo Pharma Co., Ltd. | 慢性閉塞性肺疾患治療剤 |
JP4787247B2 (ja) * | 2005-04-28 | 2011-10-05 | 大日本住友製薬株式会社 | 慢性閉塞性肺疾患治療剤 |
JPWO2006118268A1 (ja) * | 2005-04-28 | 2008-12-18 | 大日本住友製薬株式会社 | 慢性閉塞性肺疾患治療剤 |
CN101166534B (zh) * | 2005-04-28 | 2011-09-21 | 大日本住友制药株式会社 | 用于慢性阻塞性肺部疾病的治疗剂 |
US8012971B2 (en) | 2005-04-28 | 2011-09-06 | Dainippon Sumitomo Pharma Co., Ltd. | Therapeutic agent for chronic obstructive pulmonary disease |
JP2007015999A (ja) * | 2005-07-11 | 2007-01-25 | Sumitomo Chemical Co Ltd | イミノチアゾール化合物の製造方法 |
WO2007132546A1 (ja) * | 2006-05-11 | 2007-11-22 | Dainippon Sumitomo Pharma Co., Ltd. | チアゾール誘導体を有効成分とする医薬 |
US7998989B2 (en) | 2007-05-23 | 2011-08-16 | Korea Institute Of Science And Technology | 2-Imino-1,3-thiazoline-based compounds and T-type calcium channel inhibitors containing the same |
KR100863239B1 (ko) * | 2007-05-23 | 2008-10-15 | 한국과학기술연구원 | 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는t-형 칼슘 채널 저해제 |
WO2009131170A1 (ja) | 2008-04-25 | 2009-10-29 | 大日本住友製薬株式会社 | 5員環化合物 |
WO2009131171A1 (ja) | 2008-04-25 | 2009-10-29 | 大日本住友製薬株式会社 | 新規5員環化合物 |
Also Published As
Publication number | Publication date |
---|---|
CA2413000A1 (en) | 2002-01-10 |
PT1300401E (pt) | 2010-01-25 |
KR100824156B1 (ko) | 2008-04-21 |
CA2413000C (en) | 2010-01-19 |
DE60140748D1 (de) | 2010-01-21 |
US6919361B2 (en) | 2005-07-19 |
KR20030011377A (ko) | 2003-02-07 |
EP1669070A3 (en) | 2007-05-23 |
ATE451102T1 (de) | 2009-12-15 |
EP1300401A4 (en) | 2004-07-21 |
CY1109863T1 (el) | 2014-09-10 |
DK1300401T3 (da) | 2010-02-01 |
US20040072827A1 (en) | 2004-04-15 |
ES2336425T3 (es) | 2010-04-13 |
EP1300401B1 (en) | 2009-12-09 |
US7396842B2 (en) | 2008-07-08 |
KR20070086998A (ko) | 2007-08-27 |
KR100758775B1 (ko) | 2007-09-14 |
CN1620442A (zh) | 2005-05-25 |
AU2001266345B2 (en) | 2006-03-02 |
CN1944417A (zh) | 2007-04-11 |
EP1669070A2 (en) | 2006-06-14 |
CN100369903C (zh) | 2008-02-20 |
EP1300401A1 (en) | 2003-04-09 |
US20050222226A1 (en) | 2005-10-06 |
JP3785397B2 (ja) | 2006-06-14 |
TWI313266B (en) | 2009-08-11 |
AU6634501A (en) | 2002-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002002542A1 (en) | Five-membered-ring compound | |
JP3884290B2 (ja) | Hpparアルファアクチベーターとしての置換オキサゾールおよびチアゾール誘導体 | |
ES2295352T3 (es) | Derivados de tiazol o de oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas con las mismas. | |
JP2009544620A (ja) | 自己免疫疾患及び炎症のためのプロリン尿素ccr1アンタゴニスト | |
JP2004517100A (ja) | hPPARアルファアゴニストとしての置換オキサゾールおよびチアゾール | |
KR100859591B1 (ko) | Hppar-알파 수용체의 옥사졸/티아졸-유도체 활성제 | |
JP2003192591A (ja) | 5員環化合物からなる医薬 | |
JP2006169257A (ja) | 5員環化合物 | |
JP2005206515A (ja) | 5員環化合物 | |
US20070167628A1 (en) | Thiazole-2-carboxamide derivatives for use as hippar agonists in the treatment of i.a. dyslipidemia | |
WO2001047895A1 (fr) | Nouveaux composes comprenant des cycles heteroaromatiques a cinq chainons | |
WO2009131171A1 (ja) | 新規5員環化合物 | |
JPWO2006126581A1 (ja) | 組合せ医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2413000 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001266345 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027017947 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10312692 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001943850 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027017947 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018146139 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001943850 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |